Phio Pharmaceuticals Corp./$PHIO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Ticker
$PHIO
Sector
Primary listing
Employees
5
Headquarters
Website
PHIO Metrics
BasicAdvanced
$11M
-
-$2.02
0.89
-
Price and volume
Market cap
$11M
Beta
0.89
52-week high
$4.19
52-week low
$0.97
Average daily volume
363K
Financial strength
Current ratio
6.899
Quick ratio
6.426
Profitability
EBITDA (TTM)
-8.358
Management effectiveness
Return on assets (TTM)
-60.16%
Return on equity (TTM)
-107.58%
Valuation
Price to book
0.59
Price to tangible book (TTM)
0.59
Price to free cash flow (TTM)
-0.545
Free cash flow yield (TTM)
-183.57%
Free cash flow per share (TTM)
-1.854
Growth
Earnings per share change (TTM)
-83.99%
3-year earnings per share growth (CAGR)
-72.46%
PHIO News
AllArticlesVideos
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
Newsfile Corp·1 week ago
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
Newsfile Corp·2 weeks ago
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
Newsfile Corp·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phio Pharmaceuticals Corp. stock?
Phio Pharmaceuticals Corp. (PHIO) has a market cap of $11M as of February 03, 2026.
What is the P/E ratio for Phio Pharmaceuticals Corp. stock?
The price to earnings (P/E) ratio for Phio Pharmaceuticals Corp. (PHIO) stock is 0 as of February 03, 2026.
Does Phio Pharmaceuticals Corp. stock pay dividends?
No, Phio Pharmaceuticals Corp. (PHIO) stock does not pay dividends to its shareholders as of February 03, 2026.
When is the next Phio Pharmaceuticals Corp. dividend payment date?
Phio Pharmaceuticals Corp. (PHIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Phio Pharmaceuticals Corp.?
Phio Pharmaceuticals Corp. (PHIO) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.